Zimbabwe has turned down a significant US health deal worth $367m (£272m) over five years because of the United States' request for sensitive biological samples.
The decision was revealed after a official document dated December was disclosed, indicating that Head of State Emmerson Mnangagwa believed the arrangement was "unbalanced".
An official spokesperson has since stated that the United States was demanding access to genetic material for research and commercial purposes while was not willing to guarantee the resulting advantages from any future vaccines.
"We must now begin the difficult and regrettable task of scaling back our health aid in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the United States had furnished over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has urged continued dialogue to secure a deal suitable to both sides so the nation's vital HIV treatment initiative can proceed.
Broader Implications
This rejection follows a comparable situation in Kenya, where a court suspended a similar deal with the US following concerns were filed about the security of citizens' medical information.
Since returning to office last year, US President Donald Trump has reduced foreign aid and closed the key foreign aid agency.
USAID had administered aid for the US government, but Trump argued its expenditure was "wasteful" and his government was seeking direct bilateral agreements to boost openness and accountability.
Based on statements, 16 nations in Africa have to date signed these new agreements, representing over $18.3bn in committed funds.
Specifics of the Rejected Agreement
The funds for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this partnership could have provided extraordinary benefits for the people of Zimbabwe, particularly the 1.2 million presently on antiretroviral therapy via American-funded programmes," the Ambassador added.
However, government spokesperson Nick Mangwana maintained the arrangement was "asymmetrical".
"Zimbabwe was being asked to provide its biological resources and data for a long time, without any corresponding assurance of benefiting from any medical innovations – such as vaccines, diagnostics, or treatments – that could be developed from that provided information," Mangwana explained.
"Effectively, our nation would provide the raw materials for scientific discovery with no certainty that the final treatments would be accessible to our citizens if a new health crisis arise."
Sovereignty and Global Health
He also pointed out that the US's withdrawal from the global health body and its push of bilateral health agreements were undermining systems previously established via the global health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework designed to manage future global health emergencies.
"This mechanism is designed to guarantee that when a nation provides its information, the benefits – such as vaccines and treatments – are shared equitably, not monopolised exclusively by those with the capability to develop them."
Zimbabwe's reservations regarding the US deal "are not meant as opposition to America," Mangwana stressed.
"We welcome continued dialogue with our American counterparts on how future collaboration could be arranged in a manner that honours the independence and interests of both nations."
Medical Community Reaction
Medical experts stated it recognised the government's concerns, but suggested that talks must proceed considering a large portion of the country's HIV programmes depended on external financing.
"If technical issues exist, including those relating to information security or agreement terms, these can frequently be addressed through technical clarification and negotiated safeguards," it added.
The situation underscores the ongoing tensions between receiving crucial foreign assistance and safeguarding a country's data in an increasingly interconnected world.